Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web


  Free Subscription


1 Am J Med
1 BMC Gastroenterol
1 Eur J Gastroenterol Hepatol
2 Gastroenterology
2 Hepatology
5 J Hepatol
1 J Immunol
2 J Med Virol
1 J Virol
4 Lancet Gastroenterol Hepatol
6 PLoS One
2 Vaccine
1 Virology

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Med

  1. HORN CL, Jalali S, Abbott J, Stein MT, et al
    A Surprising Diagnosis: Syphilitic Gastritis and Hepatitis.
    Am J Med. 2018 Apr 10. pii: S0002-9343(18)30304.
    PubMed     Text format    

    BMC Gastroenterol

  2. YING Y, Hu YK, Jin JL, Zhang JM, et al
    Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B.
    BMC Gastroenterol. 2018;18:45.
    PubMed     Text format     Abstract available

    Eur J Gastroenterol Hepatol

  3. SPINICCI M, Emmi G, Dies L, Barilaro A, et al
    Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases.
    Eur J Gastroenterol Hepatol. 2018 Apr 11. doi: 10.1097/MEG.0000000000001132.
    PubMed     Text format     Abstract available


  4. MANDORFER M, Reiberger T, Peck-Radosavljevic M
    Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30150.
    PubMed     Text format    

  5. TAVIS JE, Lomonosova E
    NVR 3-778 Plus Pegylated Interferon-alpha Treatment for Chronic Hepatitis B Viral Infections: Could 1 + 1 = 3?
    Gastroenterology. 2018;154:481-482.
    PubMed     Text format    


  6. WENDUM D, Layese R, Ganne-Carrie N, Bourcier V, et al
    Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29927.
    PubMed     Text format     Abstract available

  7. HOUSSEL-DEBRY P, Coilly A, Fougerou-Leurent C, Jezequel C, et al
    12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29918.
    PubMed     Text format     Abstract available

    J Hepatol

  8. BRANDL K, Hartmann P, Jih LJ, Pizzo DP, et al
    Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)31973.
    PubMed     Text format     Abstract available

  9. EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Apr 9. pii: S0168-8278(18)31968.
    PubMed     Text format    

  10. ABDEL-MONEIM A, Aboud A, Abdel-Gabbar M, Zanaty MI, et al
    A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30174.
    PubMed     Text format    

  11. SUSLOV A, Heim MH, Wieland S
    New insights into hepatitis D virus (HDV) induced innate immunity: MDA5 senses HDV replication.
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)31972.
    PubMed     Text format    

  12. BILLERBECK E, Mommersteeg MC, Shlomai A, Xiao JW, et al
    Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.
    J Hepatol. 2016 May 2. pii: S0168-8278(16)30166.
    PubMed     Text format     Abstract available

    J Immunol

  13. TAN X, Ding Y, Zhu P, Dou R, et al
    Elevated Hepatic CD1d Levels Coincide with Invariant NKT Cell Defects in Chronic Hepatitis B Virus Infection.
    J Immunol. 2018 Apr 11. pii: jimmunol.1701801. doi: 10.4049/jimmunol.1701801.
    PubMed     Text format     Abstract available

    J Med Virol

  14. MOSITES E, Gounder P, Snowball M, Morris J, et al
    Hepatitis A vaccine immune response 22 years after vaccination.
    J Med Virol. 2018 Apr 12. doi: 10.1002/jmv.25089.
    PubMed     Text format     Abstract available

  15. LAGO BV, Mello FCA, Barros TM, Mello VM, et al
    Hepatitis D infection in Brazil: prevalence and geographical distribution of anti-Delta antibody.
    J Med Virol. 2018 Apr 14. doi: 10.1002/jmv.25088.
    PubMed     Text format     Abstract available

    J Virol

  16. NISHITSUJI H, Ujino S, Harada K, Shimotohno K, et al
    TIP60 Complex Inhibits Hepatitis B Virus Transcription.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


  17. EL BCHERAOUI C, Mokdad AH, Dwyer-Lindgren L, Bertozzi-Villa A, et al
    Trends and Patterns of Differences in Infectious Disease Mortality Among US Counties, 1980-2014.
    JAMA. 2018;319:1248-1260.
    PubMed     Text format     Abstract available

    Lancet Gastroenterol Hepatol

  18. JONES D, Manns MP, Terracciano L, Torbenson M, et al
    Unmet needs and new models for future trials in autoimmune hepatitis.
    Lancet Gastroenterol Hepatol. 2018;3:363-370.
    PubMed     Text format     Abstract available

    Treatment of hepatitis C: momentum still needed.
    Lancet Gastroenterol Hepatol. 2018;3:289.
    PubMed     Text format    

  20. DORE GJ
    Striving for hepatitis C virus elimination or control?
    Lancet Gastroenterol Hepatol. 2018;3:295-297.
    PubMed     Text format    

  21. GUPTA N, Nsanzimana S
    Is hepatitis C elimination possible in sub-Saharan Africa? The case of Rwanda.
    Lancet Gastroenterol Hepatol. 2018;3:302-303.
    PubMed     Text format    

    PLoS One

  22. HUGHES E, Hopkins LJ, Parker R
    Correction: Survival from alcoholic hepatitis has not improved over time.
    PLoS One. 2018;13:e0195857.
    PubMed     Text format     Abstract available

  23. FRIEDMAN A, Siewe N
    Chronic hepatitis B virus and liver fibrosis: A mathematical model.
    PLoS One. 2018;13:e0195037.
    PubMed     Text format     Abstract available

  24. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0195575.
    PubMed     Text format     Abstract available

  25. HAN B, Yuan Q, Shi Y, Wei L, et al
    The experience of discrimination of individuals living with chronic hepatitis B in four provinces of China.
    PLoS One. 2018;13:e0195455.
    PubMed     Text format     Abstract available

  26. EKO MBA JM, Bisseye C, Ntsame Ndong JM, Mombo LE, et al
    Prevalent hepatitis B surface antigen among first-time blood donors in Gabon.
    PLoS One. 2018;13:e0194285.
    PubMed     Text format     Abstract available

  27. LU Y, Jin X, Duan CA, Chang F, et al
    Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China.
    PLoS One. 2018;13:e0195117.
    PubMed     Text format     Abstract available


  28. HYER R, McGuire DK, Xing B, Jackson S, et al
    Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults.
    Vaccine. 2018 Apr 5. pii: S0264-410X(18)30436.
    PubMed     Text format     Abstract available

  29. TAVOSCHI L, Severi E, Carrillo Santisteve P, Lopalco P, et al
    Hepatitis A in the EU/EEA: The case for scaling up prevention.
    Vaccine. 2018 Apr 5. pii: S0264-410X(18)30299.
    PubMed     Text format    


  30. KRAPCHEV VB, Rychlowska M, Chmielewska A, Zimmer K, et al
    Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice.
    Virology. 2018;519:33-41.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.